Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer

References

• Zhuang HQ Yuan ZY Process in the mechanisms of EGFR inhibitor combined with radiotherapy Chin Clin Oncol 2009 14 560 563
   Google Scholar
• Hughes S Liong J Miah A A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study J Thorac Oncol 2008 3 648 651 18520806
   PubMed Web of Science ®Google Scholar
• Hallqvist A Wagenius G Rylander H Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: SATELLITE – a phase II study from the Swedish Lung Cancer Study Group Lung Cancer 2010 71 166 172 20541833
   PubMed Web of Science ®Google Scholar
• Kotsakis AR Ramalingam SS Tarhini AA Heron DE Smith R Friedland D Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC) J Clin Oncol 2011 29 Suppl Abstr 7019
   Google Scholar
• Blumenschein GRJr Paulus R Curran WJ Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 J Clin Oncol 2011 29 2312 2318 21555682
   PubMed Web of Science ®Google Scholar
• Dingemans A-MB van Baardwijk G Reymen A Determination of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin-vinorelbine for patients with stage III non-small cell lung cancer (NSCLC): a phase I study (NCT00522886) J Thorac Oncol 2011 6 Abstr MO02.02
   Web of Science ®Google Scholar
• Govindan R Bogart J Stinchcombe T Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407 J Clin Oncol 2011 29 3120 3125 21747084
   PubMed Web of Science ®Google Scholar
• Masters G Cetuximab no benefit with chemoradiation in lung cancer Abstract PL03 presented at the 15th World Conference on Lung Cancer, International Association for the Study of Lung Cancer October 27–30, 2013 Sydney, Australia
   Google Scholar
• Zhou LL Liu J Gong R-M A Phase II trial of nimotuzumab in combination with chemoradiotherapy in locally advanced lung squamous cell carcinoma J Thorac Oncol 2011 6 Abstr P4.280
   Web of Science ®Google Scholar
• Ready N Janne PA Bogart J Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial J Thorac Oncol 2010 5 1382 1390 20686428
   PubMed Web of Science ®Google Scholar
• Kelly K Chansky K Gaspar LE Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 2008 26 2450 2456 18378568
   PubMed Web of Science ®Google Scholar
• Rothschild S Bucher SE Bernier J Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial Int J Radiat Oncol Biol Phys 2011 80 126 132 20646869
   PubMed Web of Science ®Google Scholar
• Ball D Burmeister B Mitchell P Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (‘‘CRITICAL’’) J Thorac Oncol 2007 2 S633 S634
   Web of Science ®Google Scholar
• Center B Petty WJ Ayala D A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer J Thorac Oncol 2010 5 69 74 20035186
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE Morris DE Lee CB Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer J Thorac Oncol 2008 3 250 257 18317067
   PubMed Web of Science ®Google Scholar
• Ohe Y Nishiwaki Y Yokoyama A Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402 J Clin Oncol 2010 28 Suppl 15 Abstr 7084
   Web of Science ®Google Scholar
• Wang J Xia TY Wang YJ Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2011 81 e59 e65 21345607
   PubMed Web of Science ®Google Scholar
• Komaki R Blumenschein G Wistuba I Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer J Clin Oncol 2011 29 Suppl Abstr 7020
   Google Scholar
• Ramella S Trodella L Alberti A MultimodAlity treatment with RadiochemoTherapy and Erlotinib in advanced NSCLC (MARTE trial) J Thorac Oncol 2011 6 Abstr MO02.04
   Web of Science ®Google Scholar
• Wan J Cohen V Agulnik J Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 2009 75 Suppl 1 S110
   Web of Science ®Google Scholar
• Chang CC Chi KH Kao SJ Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience Lung Cancer 2011 73 189 194 21247653
   PubMed Web of Science ®Google Scholar
• Zhuang HQ Yuan ZY Wang P Research progress on the mechanisms of combined bevacizumab and radiotherapy Recent Pat Anticancer Drug Discov 2014 9 129 134 24032532
   PubMed Web of Science ®Google Scholar
• Zhuang HQ Yuan ZY Process in the mechanisms of endostatin combined with radiotherapy Cancer Lett 2009 282 9 13 19136200
   PubMed Web of Science ®Google Scholar
• Lind JS Senan S Smit EF Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer J Clin Oncol 2012 30 e104 e108 22331948
   PubMed Web of Science ®Google Scholar
• Spigel DR Hainsworth JD Yardley DA Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 2010 28 43 48 19901100
   PubMed Web of Science ®Google Scholar
• Mangoni M Vozenin MC Biti G Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead Br J Cancer 2012 107 308 314 22691970
   PubMed Web of Science ®Google Scholar
• Socinski MA Stinchcombe TE Moore DT Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial J Clin Oncol 2012 30 3953 3959 23045594
   PubMed Web of Science ®Google Scholar
• Sandler A Gray R Perry MC Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 2006 355 2542 2550 17167137
   PubMed Web of Science ®Google Scholar
• Stinchcombe T Socinski M Moore D Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) J Clin Oncol 2011 29 Suppl Abstr 7016
   Google Scholar
• Ma S Xu Y Sun X Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: preliminary results of a phase II study J Clin Oncol 2011 29 Suppl Abstr 7043
   Google Scholar
• Zhou QC Bao Y Yu ZH A prospective phase I/II study of recombinant endostatin (Endostar) combined with concurrent radio-chemotherapy in patients with unresectable stage III non-small cell lung cancer Chin J Radiat Oncol 2012 21 500 504
   Google Scholar
• Bagri A Kouros-Mehr H Leong KG Plowman GD Use of antiVEGF adjuvant therapy in cancer: challenges and rationale Trends Mol Med 2010 16 122 132 20189876
   PubMed Web of Science ®Google Scholar
• Wachsberger P Burd R Dicker AP Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction Clin Cancer Res 2003 9 1957 1971 12796357
   PubMed Web of Science ®Google Scholar
• Sos ML Rode HB Heynck S Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation Cancer Res 2010 70 868 874 20103621
   PubMed Web of Science ®Google Scholar
• Das AK Sato M Story MD Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation Cancer Res 2006 66 9601 9608 17018617
   PubMed Web of Science ®Google Scholar
• Taniguchi K Okami J Kodama K Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib Cancer Sci 2008 99 929 935 18325048
   PubMed Web of Science ®Google Scholar
• Winkler F Kozin SV Tong RT Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 2004 6 553 563 15607960
   PubMed Web of Science ®Google Scholar
• Tong RT Boucher Y Kozin SV Winkler F Hicklin DJ Jain RK Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 2004 64 3731 3736 15172975
   PubMed Web of Science ®Google Scholar
• Yi HG Kim HJ Kim YJ Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Lung Cancer 2009 65 80 84 19059670
   PubMed Web of Science ®Google Scholar
• Koh PK Faivre-Finn C Blackhall FH Target agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy Cancer Treat Rev 2012 38 626 640 22196919
   PubMed Web of Science ®Google Scholar
• Zhuang HQ Yuan ZY Wang J Research progress on criteria for discontinuation of EGFR inhibitor therapy Onco Targets Ther 2012 5 263 270 23082072
   PubMed Web of Science ®Google Scholar
• Guo S Zou J Wang G Advances in the proteomic discovery of novel therapeutic targets in cancer Drug Des Devel Ther 2013 7 1259 1271
   PubMed Web of Science ®Google Scholar
• Sakhrani NM Padh H Organelle targeting: third level of drug targeting Drug Des Devel Ther 2013 7 585 599
   PubMed Web of Science ®Google Scholar
• Zhuang H Yuan Z Wang J Zhao L Pang Q Wang P Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma Drug Des Devel Ther 2013 7 1179 1186
   PubMed Web of Science ®Google Scholar